That's how I read it as well but the analyst report from Roth had an increase of SD (probably just post enrolment scan????) and no change for CR and PR (I guess them still remaining CR and PR are positive) so holders will interpret that as IMU did a data cut but somehow didn't announced this PS news to the ASX???? But they didn't so there was nothing to announce, no doubt some would have sold because they thought this was the data cut along with the adverse reaction from a patient who was only on the clinical trial for 2 months.
